Pre-made Cinpanemab benchmark antibody ( Whole mAb, anti-SNCA therapeutic antibody, Anti-NACP/PARK1/PARK4/PD1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-106
Pre-Made Cinpanemab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cinpanemab (BIIB 054), a monoclonal antibody against pathologic alpha-synuclein aggregates, is being developed by Biogen, for the treatment of Parkinson's disease.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Cinpanemab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||6ct7:HL:AB|
|99% SI Structure||None|
|95-98% SI Structure||None|